Abstract: Pharmaceutical compositions for intranasal administration comprising (a) calcitonin and (b) at least one absorption enhancer selected from the group consisting of benzyl alcohol, ethanol, thiamine or a salt thereof, salicylic acid or a salt thereof, capric acid or a salt thereof, Macrogol 400, pyridoxal or a salt thereof, malic acid or a salt thereof and pyrophosphoric acid or a salt thereof, in (c) a liquid diluent or carrier, suitable for application to the nasal mucosa.

Abstract: A compound of formula I ##STR1## wherein R is H or R'CO wherein R'CO is an acyl radical of a carboxylic acid,Y.sub.1 is the radical linked to an alpha carbon atom an .alpha.-amino acid,Y.sub.2 is the radical linked to an alpha carbon atom of an .alpha.-amino acid, ##STR2## --CH.sub.2 --S--S--CH.sub.2 --CH.sub.2 --COOH, --(CH.sub.2).sub.p --COOH or --CH.sub.2 --S--Y.sub.3,Y.sub.3 is (C.sub.1-4)alkyl or benzyl optionally substituted by methyl or methoxy,or CH.sub.3 CO--NH--CH.sub.2 --,n is 1 to 4,A.sub.6 is Thr or D-Thr,p is 3 to 5,A.sub.8 is the aminoacyl radical of a neutral, lipophilic L-.alpha.-aminoacid,A.sub.9 is the aminoacyl radical of a neutral, lipophilic L- or D-.alpha.-aminoacid,Z is a polypeptide radical corresponding to the polypeptide radical in positions 10 to 31 of a natural calcitonin or a derivative or analogue thereof having a hypocalcemic effect,wherein, when there is more than one Y.sub.1 radical, these are the same or different, and with the exception of radical A.sub.

Abstract: Method for regulating serum calcium levels in mammals by orally administering a composition which includes a polypeptide hormone such as parathyroid hormone (PTH) or calcitonin. The polypeptide hormone is protected from destruction in the digestive tract by encapsulation in liposomes. The liposome preferably includes a cationic amphiphilic agent so that the surface of the liposome has a net positive charge. Agents for enhancing the action of the liposome encapsulated hormones are also disclosed.

Abstract: Pharmaceutical compositions for intranasal administration comprising (a) calcitonin and (b) at least one absorption enhancer selected from the group consisting of benzyl alcohol, ethanol, thiamine or a salt thereof, salicylic acid or a salt thereof, capric acid or a salt thereof, Macrogol 400, pyridoxal or a salt thereof, malic acid or a salt thereof and pyrophosphoric acid or a salt thereof, in (c) a liquid diluent or carrier, suitable for application to the nasal mucosa.

Abstract: Compounds of the formula: ##STR1## wherein R.sub.1 is a moiety selected from the group consisting of ##STR2## R.sub.2 -R.sub.22 are amino acid moieties wherein R.sub.2 is an optional moiety which when present is selected from the group consisting of Ser and Gly,R.sub.8 is Leu or Val,R.sub.10 is Gln, Lys, or Gly,R.sub.11, R.sub.14, and R.sub.20 are each independently selected from the group consisting of Gln and Lys,R.sub.12 is Leu or Trp,R.sub.13 is Gln or Ser,R.sub.17 is Gln or His,R.sub.19 is Leu or Cys,R.sub.21 is Gln or Thr,R.sub.22 is an optional moiety which when present is selected from the group consisting of Leu and Tyr;R.sub.24 -R.sub.

Abstract: New peptides are disclosed which have biological activity of the same type as calcitonins and which have been modified with desaminocysteine and .alpha.-aminosuberic acid at the N-terminal and new amino acid substituents at the penultimate position of the C-terminal.

Abstract: New calcitonin analogs are disclosed which have biological activity of the same type as known calcitonins and which have a D-amino acid substituent in at least one of the positions 31 and 32 instead of the natural L-amino acid units. The calcitonin analog may be analogs of salmon, eel, chicken, bovine, porcine, ovine, murine or human calcitonins.

Abstract: New polypeptides are disclosed which have biological activity of the same degree as known calcitonins and which have amino acid substituents in position 31 instead of the naturally occuring amino acids--Thr, Ala, Val.

Abstract: A pharmaceutical composition is disclosed which comprises a physiologically active substance possessing peptide bonds in its structure and being inactivable by digestive enzymes, the active substance being other than insulin, and a synthetic chymotrypsin inhibitor. The composition is particularly suitable for intestinal absorption of the active substance.

Abstract: Human calcitonin in the form of four components and process for their isolation from C-cells material.